AlphaSense builds generative AI tools incorporating hundreds of millions of financial and business documents. The company says 88% of the S&P 100 are among its 5,000 clients, including Amazon, Nvidia,

Moelis' incoming CEO Navid Mahmoodzadegan told investors on Tuesday that he is optimistic about the dealmaking environment, as confidence returns following a pause in April triggered by U.S. tariff threats.

Circle's CRCL stock debuted on the NYSE on June 5 when it opened at $69, more than 124% higher than the IPO price of $31. The CRCL stock hit a record high of $138.57 on 9 June as the news of ETF filings flew in. However, the stock closed at $ 107.10 on 10 June, a 7% drop in a day.

Now, Brian Quintenz — a former Wall Street regulator who has been tapped to lead the small but powerful Commodity Futures Trading Commission — is preparing to take over an agency in disarray.

Bloomberg says Zuckerberg has prioritized recruiting for the new team, referred internally as a “superintelligence group.” He intends to recruit from a group of AI researchers and engineers whom he has met in recent weeks at his homes in Lake Tahoe and Palo Alto.

As they process President Trump's chaotic tariffs and other economic policies, some of the country's most powerful CEOs are moving from denial and bargaining to public anger and depression.

Though stock splits come in two varieties -- forward and reverse -- investors gravitate to one far more than the other. Three high-profile companies have announced stock splits in 2025, with Fastenal being the first to conduct a forward split.

UnitedHealth weighs $1B deal for Banmedica - report. Chime Financial IPO demand blows past share supply ahead of pricing. U.S should treat Taiwan as partner, not as an adversary, says AmCham

Los analistas de empresas como Barclays Plc y JPMorgan Chase & Co. ven un mayor potencial alcista para las acciones estadounidenses, en parte porque esperan que los inversores institucionales abandonen su postura cautelosa y aumenten su exposición a la renta variable.

Drugs like Ozempic pose one of the most critical threats to the restaurant chain’s business, Redburn Atlantic says.